Belimumab In Early Systemic Lupus Erythematosus

Inclusion Criteria: * Clinical diagnosis of SLE according to the 1997 American College of Rheumatology (ACR) classification criteria or 2019 EULAR/ACR classification criteria within three months, which is autoantibody-positive (antinuclear antibody titers ≥1:80, anti-double-stranded DNA antibodies, or both) * 18-75 years of age * body weight 45-80kg * Disease duration of SLE ≤ 6months * SELENA-2K score ≥6 scores * Negative pregnancy test for child-bearing women at screening and baseline * Provide written informed consent Exclusion Criteria: * Known to be allergic to Prednisone Acetate, Meprednisone, Hydroxychloroquine, and Immunosuppressants including Mycophenolate Mofetil, Cyclophosphamide,et al * Active serious neuropsychiatric systemic lupus erythematosus or other severe situations of SLE who need pulse steroid treatment * Abnormal liver function (ALT or AST is 2 times higher than normal) * Pregnancy or breastfeeding women; * Have a history of malignant tumors; * Have any serious acute, chronic or recurrent infectious disease (such as pneumonia or active stage of pyelitis, recurrent pneumonia, chronic bronchiectasis and tuberculosis) * Chronic infections, such as Hepatitis B virus or hepatitis B and C and HIV; * Previous visual obstruction, monocular dysfunction and cataract; * Cardiac insufficiency with metabolic imbalance or severe high blood pressure (systolic pressure \> 160mmHg or diastolic pressure \> 100mmHg) or diabetics; * Active hemorrhage or peptic ulcer; * With other concommitant autoimmune disease; * Receipt of B-cell-targeted therapy (including belimumab) within 1 year before randomization. * Participated in other drugs clinical trials within 4 weeks.